Announcement

Collapse
No announcement yet.

Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab


    Vaccine. 2019 Nov 22. pii: S0264-410X(19)31470-7. doi: 10.1016/j.vaccine.2019.10.081. [Epub ahead of print] Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab.

    Furer V1, Zisman D2, Kaufman I3, Arad U1, Berman M3, Sarbagil-Maman H3, Elias M2, Hadad A2, Paran D1, Drori Y4, Friedman N4, Mandelboim M5, Elkayam O6.
    Author information

    1 Department of Rheumatology, Tel Aviv Medical Center, Israel; The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 2 Unit of Rheumatology, Carmel Medical Center, Israel. 3 Department of Rheumatology, Tel Aviv Medical Center, Israel. 4 Central Virology Laboratory, Sheba Medical Center, Tel Hashomer, Israel; The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 5 Unit of Rheumatology, Carmel Medical Center, Israel; Central Virology Laboratory, Sheba Medical Center, Tel Hashomer, Israel. 6 Department of Rheumatology, Tel Aviv Medical Center, Israel; The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: Oribe14@gmail.com.

    Abstract

    OBJECTIVE:

    To assess the immunogenicity and safety of vaccination against seasonal influenza in psoriatic arthritis (PsA) patients treated with secukinumab versus healthy controls (HC).
    METHODS:

    PsA patients administered secukinumab for ≥3 months and HC received the Sanofi Pasteur vaccine composed of 3 antigens (H3N3, H1N1, and B) and underwent clinical and laboratory assessments on the day of vaccination and 4-6 weeks later. Immunogenicity of the vaccine was evaluated by hemagglutination inhibition assay against those 3 antigens. Responders to each antigen were defined by a 4-fold increase in the antigen titer or by seroconversion in patients whose baseline level was <1/40.
    RESULTS:

    Thirty-two consecutive PsA patients treated with secukinumab for ≥3 months comprised the study group, 10 of whom received concomitant conventional synthetic disease-modifying drugs, mostly methotrexate. There were 17 age- and gender-matched HC (median age 48.5 years, 6 females). The geometric mean titers of each antigen increased significantly in both groups. The number of responders in each group was similar for H3N2 and H1N1, and significantly higher for B/Brisbane in the PsA group. The proportion of patients with a seroprotective level (a titer >1/40) was high and similar in both groups. There was no correlation between the response rate and age, gender, or selected parameters of disease activity (tender/swollen joint counts, Leeds enthesitis index, physician and patient global assessment, psoriasis area severity index, and C-reactive protein). No disease exacerbation was observed following the vaccination. No serious adverse effects were observed in both groups during the study period.
    CONCLUSION:

    Secukinumab treatment does not affect the humoral response to influenza vaccine of patients with PsA.
    Copyright 2019. Published by Elsevier Ltd.


    KEYWORDS:

    Influenza vaccine; Psoriatic arthritis; Secukinumab

    PMID: 31767465 DOI: 10.1016/j.vaccine.2019.10.081

Working...
X